Sarcoma Sarcomes | Sarcomas Selected papers
Articles seleccionats Artículos seleccionados Demetri G.D., Reichardt P., Kang Y.K., Blay J.Y., Rutkowski P., Gelderblom H., Hohenberger P., Leahy M., von Mehren M., Joensuu H., Badalamenti G., Blackstein M., Le Cesne A., Schöffski P., Maki R.G., Bauer S., Nguyen B.B., Xu J., Nishida T., Chung J., Kappeler C., Kuss I., Laurent D.,Garcia del Muro X., Casali PG; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381:295-302. Sainz-Jaspeado, M., Huertas-Martinez, J., LagaresTena L., Liberal J.M., Mateo-Lozano, S., de Alava, E., de Torres, C., Mora J., del Muro, X. G., Tirado, O.M. EphA2-Induced Angiogenesis in Ewing Sarcoma Cells Works through bFGF Production and Is Dependent on Caveolin-1. PLoS One 2013: 8: e71449. Martin-Liberal J., Lopez-Pousa A., Broto J.M., Cubedo R., Gallego O., Brendel E., Tirado O.M., Del Muro X.G. Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. Invest New Drugs 201; Jun 16. Investigational New Drugs. 2014 Apr;32(2):287-94. doi: 10.1007/s10637-013-9989-9. Epub 2013 Jun 26. Sengupta, A., Rahman M., Mateo-LozanoS., Tirado O.M., Notario V. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing’s sarcoma. International Journal of Oncology. 2013 Sep;43(3):803-12.
69
IDIBELL Institut d’Investigació Biomèdica de Bellvitge - ANNUAL REPORT 2013